[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 64 of about 64
1. Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, Blaakaer J, Kjaer SK: Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2006 Apr;15(4):798-803
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer.
  • OBJECTIVE: Smoking and overweight are associated with poorer prognosis in several cancer types.
  • The prognostic effect of smoking and body mass index (BMI) on ovarian cancer is unknown.
  • METHODS: Ovarian cancer cases were from the Danish MALOVA (MALignant OVArian cancer) study.
  • Cox regression models were used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for ovarian cancer-specific death in relation to smoking variables and BMI.
  • RESULTS: A total of 295 women with stage III epithelial ovarian cancer were identified and followed to death or for a median of 7.3 years (range, 5.4-9.5 years).
  • Current smokers had a significantly increased risk of ovarian cancer death compared with never smokers in multivariate Cox analysis (HR, 1.65; 95% CI, 1.22-2.24).
  • Overweight women also had an increased risk of ovarian cancer death (HR, 1.83; 95% CI, 1.38-2.42) compared with normal-weight women.
  • CONCLUSION: Smoking at the time of diagnosis and premorbid overweight were negative prognostic factors for ovarian cancer-specific survival.
  • [MeSH-major] Body Mass Index. Carcinoma / epidemiology. Obesity / complications. Ovarian Neoplasms / epidemiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614126.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA, Gynecologic Oncology Group Phase III Trial: Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol; 2008 Jul 20;26(21):3598-606
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
  • PURPOSE: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P).
  • PATIENTS AND METHODS: Single nucleotide polymorphism analysis was carried out by direct pyrosequencing at two sites (codon 118 and C8092A) in ERCC1 in leukocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172 and were randomly assigned to intraperitoneal or intravenous C+P.
  • Women with the C8092A C/A or A/A genotypes compared with the C/C genotype had an increased risk of disease progression (hazard ratio [HR] = 1.44; 95% CI, 1.06 to 1.94; P = .018) and death (HR = 1.50; 95% CI, 1.07 to 2.09; P = .018).
  • Median PFS and OS were 6 and 17 months shorter for women with the C8092A C/A or A/A genotypes versus the C/C genotype, respectively.


3. Marabese M, Marchini S, Marrazzo E, Mariani P, Cattaneo D, Fossati R, Compagnoni A, Signorelli M, Moll UM, Codegoni AM, Broggini M: Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer; 2008 Jan;44(1):131-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.
  • The p53 gene has been investigated for its role in epithelial ovarian cancer but data collected until now are contradictory.
  • Here, we used quantitative real time RT-PCR to determine expression levels of TAp53, TAp73 and their N-terminal splice variants in a cohort of 169 ovarian cancer patients with stage I and stage III disease.
  • The TAp73 levels in stage III biopsies differed by 100-fold depending on the p53 status and overall survival appears to be significantly related to DeltaNp73 expression.
  • In conclusion, these data suggest that at least in our patient cohort p53 and p73 expression levels are not correlated to malignant progression of ovarian cancer.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Genes, p53. Mutation / genetics. Nuclear Proteins / metabolism. Ovarian Neoplasms / genetics. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039564.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093853; United States / NCI NIH HHS / CA / R01 CA093853-05S2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ NIHMS178504; NLM/ PMC4286202
  •  go-up   go-down


Advertisement
4. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C: Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1014-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
  • The aim of the study was to determine if biomarker expression could help discriminate between short-term and long-term survivors in women with advanced ovarian cancer.
  • Fifty-one patients with stage III ovarian cancer were selected for the study, which included 28 short-term survivors (death from ovarian cancer within 18 months) and 23 long-term survivors (alive for more than 5 years).
  • There was no difference between the two groups with respect to FIGO substage, age, World Health Organization score, and first-line platinum therapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / mortality. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343177.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Ki-67 Antigen; 0 / Platinum Compounds
  •  go-up   go-down


5. Riedinger JM, Mousseau M, Gauchez AS: [Contribution of dynamic interpretation of CA 125 measurements to the understanding of an atypical clinical case]. Ann Biol Clin (Paris); 2008 May-Jun;66(3):333-40
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Contribution de l'interprétation dynamique du CA 125 dans la compréhension d'un cas clinique atypique.
  • But analysis of marker kinetics can also help improve our understanding of the natural history of different types of cancer and their evolution under treatment.
  • This application is illustrated by an analysis of CA 125 kinetics measured in a patient with stage III ovarian cancer treated with multiple lines of chemotherapy and who had a survival time of 9 years.
  • [MeSH-major] CA-125 Antigen / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18558573.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


6. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med; 2006 Jan 5;354(1):34-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
  • BACKGROUND: Standard chemotherapy for newly diagnosed ovarian cancer is a platinum-taxane combination.
  • The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer.
  • METHODS: We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm to receive 135 mg of intravenous paclitaxel per square meter of body-surface area over a 24-hour period followed by either 75 mg of intravenous cisplatin per square meter on day 2 (intravenous-therapy group) or 100 mg of intraperitoneal cisplatin per square meter on day 2 and 60 mg of intraperitoneal paclitaxel per square meter on day 8 (intraperitoneal-therapy group).
  • CONCLUSIONS: As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Abdominal Pain / chemically induced. Adult. Aged. Aged, 80 and over. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / surgery. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / drug therapy. Quality of Life. Survival Analysis


7. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM: Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer; 2007 Feb 15;109(4):692-702
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
  • Because women with advanced ovarian cancer have poor outcomes, it is imperative to continue exploring for novel therapies.
  • The MEDLINE, EMBASE, and Cochrane Library databases were searched up to January 2006 for randomized trials that compared first-line intraperitoneal-containing chemotherapy with first-line intravenous chemotherapy in the treatment of women with stage III epithelial ovarian cancer.
  • Seven randomized, controlled trials were identified, including 3 large Phase III trials and 4 smaller randomized trials.
  • The 3 large Phase III trials detected statistically significant overall survival benefits with intraperitoneal cisplatin-containing chemotherapy compared with intravenous chemotherapy alone.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Infusions, Parenteral. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase III as Topic. Female. Humans. Neoplasm Staging. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238181.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


8. Grénman S, Wiklund T, Jalkanen J, Kuoppala T, Mäenpää J, Kuronen A, Leminen A, Puistola U, Vuolo-Merilä P, Salmi T, Vuento M, Yliskoski M, Itälä M, Helenius H, Joensuu H, Lehtovirta P: A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer; 2006 Sep;42(14):2196-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study.
  • Women with stage III ovarian cancer and with < or = 2 cm residual tumour were randomly assigned to receive either conventionally dosed chemotherapy (group A) or HDCT (group B).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893642.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD: Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol; 2007 Sep;106(3):476-81
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
  • OBJECTIVE: To evaluate the cost-effectiveness of intraperitoneal cisplatin and paclitaxel chemotherapy as front-line treatment for patients with Stage III epithelial ovarian cancer following optimal primary cytoreductive surgery.
  • METHODS: Based on Gynecologic Oncology Group protocols #172 and #158, a decision analysis model was created to compare two treatment strategies for patients with optimal residual disease Stage III ovarian cancer:.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / economics. Ovarian Neoplasms / drug therapy


10. Menczer J, Golan A, Levy T: Platin sensitivity and long-term survival in Stage III epithelial ovarian cancer patients. Eur J Gynaecol Oncol; 2008;29(5):473-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin sensitivity and long-term survival in Stage III epithelial ovarian cancer patients.
  • PURPOSE: The aim of the present study was to assess the effect of platin sensitivity on long-term survival of Stage III epithelial ovarian cancer (EOC) patients.
  • METHODS: The records of all histologically confirmed Stage III EOC and PPC patients diagnosed during 1995-2006 were reviewed.
  • RESULTS: Among 58 Stage III patients, 20 had long-term and 18 short-term survival.
  • [MeSH-major] Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / mortality

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051815.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


11. Yemelyanova AV, Cosin JA, Bidus MA, Boice CR, Seidman JD: Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer; 2008 May-Jun;18(3):465-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening.
  • The progression of ovarian carcinoma from stage I when it is confined to the ovaries and curable to disseminated abdominal disease, which is usually fatal, is poorly understood.
  • An accurate understanding of this process is fundamental to designing, testing, and implementing an effective screening program for ovarian cancer.
  • Pathologic features of the primary ovarian tumors in 41 FIGO stage I ovarian carcinomas were compared with those in 40 stage III carcinomas.
  • The primary ovarian tumors in stage I cases, when compared with stage III, respectively, were significantly larger (15.4 versus 9.8 cm), were less frequently bilateral (12% versus 75%), more frequently contained a noninvasive component (88% versus 30%), had a higher proportion of a noninvasive component (42% versus 8%), and were more often nonserous (83% versus 20%) (P < 0.001 for all five comparisons).
  • There are significant pathologic differences between the primary ovarian tumors in stage I and III ovarian carcinomas that are very difficult to explain by a simple temporal progression.
  • These findings along with the growing body of literature suggest that early- and advanced-stage ovarian cancers are in many instances biologically different entities.
  • This knowledge may have significant implications for our understanding of the biology of early- and advanced-stage ovarian cancer and therefore on the development of screening strategies for ovarian cancer.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Neoplasms, Glandular and Epithelial / mortality. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868343.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Pavlidis N: Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:241-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma.
  • The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma.
  • We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery and received platinum-based chemotherapy.
  • Proangiogenetic factor VEGF is highly expressed in advanced-stage ovarian carcinomas.
  • The findings of this study may offer support for considering VEGF-targeted therapeutics in ovarian cancer treatment research.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antigens, CD34 / biosynthesis. Neovascularization, Pathologic / physiopathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Thrombospondin 1 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515598.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Platinum Compounds; 0 / Thrombospondin 1; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


13. Friedlander M: Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy? Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S20-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?
  • The optimal management of women with optimally debulked stage III ovarian cancer is contentious.
  • Being on the negative side in the debate, I will provide compelling reasons why systemic chemotherapy should remain the standard of care but argue that dose-dense weekly paclitaxel rather than the 3 weekly schedules should be adopted based on the results of the Japanese Gynecologic Oncology Group study.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975355.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Alberts DS, Hannigan EV, Liu PY, Jiang C, Wilczynski S, Copeland L, Markman M: Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol Oncol; 2006 Jan;100(1):133-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.
  • OBJECTIVE: Despite the improvement in progression-free and overall survival in patients with advanced ovarian cancer associated with platinum-taxane chemotherapy, strategies are needed to prevent the greater than 70% recurrence rate.
  • METHOD: The Southwest Oncology Group (SWOG) initiated a phase III intergroup trial of alpha-interferon (IFNalpha-26, Schering-Plough, Kenilworth, NJ) in weekly doses of 50 x 10(6) IU (for 6 doses) versus observation only in patients with no pathological evidence of residual disease at second-look surgery in 1988.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16153694.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


15. Petit T, Velten M, d'Hombres A, Marchal C, Montbarbon X, Mornex F, Quetin P, Gérard JP, Romestaing P, Carrie C: Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol; 2007 Jan;104(1):104-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
  • OBJECTIVE: Attempts to increase survival in stage III ovarian cancer patients with minimal residual disease at second-look laparotomy have included consolidation radiotherapy.
  • We present long-term survival of 106 consecutive patients treated between 1983 and 1993 in 4 French institutions for stage III ovarian adenocarcinoma with first-look debulking, cisplatin-based chemotherapy, second-look surgery with a residual disease <1 cm and consolidation radiotherapy.
  • CONCLUSION: This sequential treatment with final consolidation abdominopelvic radiotherapy is an effective treatment for a selected group of stage III ovarian cancer patients with a high intestinal toxicity incidence.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Ovarian Neoplasms / radiotherapy. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16987544.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Rahaman J, Dottino P, Jennings TS, Holland J, Cohen CJ: The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):19-25
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients.
  • In a single-institution retrospective cohort study, 230 patients were treated for stage III primary ovarian cancer and 175 became eligible for second-look operations by virtue of a complete clinical response after primary surgical cytoreduction and platinum-based combination chemotherapy.
  • Five-year survival for all the 230 stage III ovarian cancers was 43.4%.
  • Patients with suboptimal debulking at primary surgery for stage III ovarian cancer appear to achieve a survival benefit from second-look surgical procedures, presumably from the early identification and treatment of residual disease.
  • [MeSH-major] Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1258; author reply 1259 [16343227.001]
  • (PMID = 15670292.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


17. Wagreich A, Salame G, Lee YC, Abulafia O: Advanced ovarian carcinoma following bilateral uterine artery embolization: a case report. J Reprod Med; 2009 May;54(5):325-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced ovarian carcinoma following bilateral uterine artery embolization: a case report.
  • Nine months after the procedure she was diagnosed with stage III ovarian carcinoma.
  • CONCLUSION: Patients undergoing bilateral uterine artery embolization should be informed of the possibility of preexisting or potential subsequent development of ovarian carcinoma, reflecting the lack of an effective screening method for this disease.
  • [MeSH-major] Leiomyoma / therapy. Ovarian Neoplasms / diagnosis. Uterine Artery Embolization / adverse effects. Uterine Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / surgery. Cisplatin / administration & dosage. Female. Humans. Neoplasm Staging. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Reprod Med. 2010 Mar-Apr;55(3-4):179; author reply 179-80 [20506684.001]
  • (PMID = 19517700.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH: Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol; 2008 Jun 1;26(16):2674-82
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
  • PURPOSE: To compare the safety and efficacy of carboplatin and paclitaxel administered with or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with advanced ovarian or primary peritoneal cancer.
  • PATIENTS AND METHODS: Seven hundred sixty-two patients with stage IV or suboptimally debulked stage III ovarian or primary peritoneal cancer were randomly assigned to receive either valspodar 5 mg/kg every 6 hours for 12 doses, paclitaxel 80 mg/m(2), and carboplatin area under the curve (AUC) 6 (PC-PSC; n = 381) or paclitaxel 175 mg/m(2) and carboplatin AUC 6 (PC; n = 381).
  • CONCLUSION: The addition of valspodar to PC did not improve TTP or OS and was more toxic compared with PC in untreated patients with advanced ovarian or primary peritoneal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporins / therapeutic use. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jun 1;26(16):2616-8 [18509172.001]
  • (PMID = 18509179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 121584-18-7 / valspodar; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


19. Delemer-Lefebvre M, Ascencio M, Cottu PH, Villet R, Vinatier D, Collinet P: [Intraperitoneal chemotherapy in ovarian cancer]. Gynecol Obstet Fertil; 2007 Sep;35(9):791-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraperitoneal chemotherapy in ovarian cancer].
  • [Transliterated title] Chimiothérapie intrapéritonéale dans le cancer de l'ovaire.
  • Ovarian cancer represents 4500 new cases a year in France and the prognosis of such tumor is not yet clear, even for the early stages.
  • Recently, five therapeutic trials were published concerning the intra-peritoneal chemotherapy of ovarian cancer stage III in patients to whom an optimal debulking surgery had been done.
  • These results have demonstrated the necessity to consider the intra-peritoneal adjuvant chemotherapy as a treatment option in patients with epithelial ovarian cancer stage III.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17719824.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP, Gynecologic Oncology Group Study: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2007 Aug 20;25(24):3621-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: Conflicting results on prognostic factors for advanced epithelial ovarian cancer (EOC) have been reported because of small sample size and heterogeneity of study population.
  • PATIENTS AND METHODS: A retrospective review of demographic, pathologic, treatment, and outcome data from 1,895 patients with International Federation of Gynecology and Obstetrics stage III EOC who had undergone primary surgery followed by six cycles of intravenous platinum/paclitaxel was conducted.
  • CONCLUSION: Age, PS, tumor histology, and residual tumor volume were independent predictors of prognosis in patients with stage III EOC.
  • [MeSH-major] Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704411.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


21. Chua TC, Robertson G, Liauw W, Morris DL: Salvage cytoreduction for chemorefractory ovarian cancer with peritoneal carcinomatosis: a last chance or futile efforts? Aust N Z J Obstet Gynaecol; 2010 Oct;50(5):478-84
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage cytoreduction for chemorefractory ovarian cancer with peritoneal carcinomatosis: a last chance or futile efforts?
  • BACKGROUND: The role of secondary cytoreductive surgery in recurrent ovarian cancer in the presence of carcinomatosis is increasingly accepted as being an effective management strategy for selected patients.
  • The objective of this study was to evaluate if cytoreduction of peritoneal carcinomatosis in patients with chemorefractory recurrent ovarian cancer as salvage treatment confers any survival benefits.
  • METHODS: A retrospective review was performed on patients with chemorefractory ovarian cancer with peritoneal carcinomatosis who underwent cytoreduction as a salvage treatment.
  • RESULTS: A total of 16 patients were identified, of which 15 patients (94%) had FIGO Stage III ovarian cancer at initial diagnosis.
  • CONCLUSIONS: Salvage cytoreduction may be considered a last chance effort to prolong survival in this group of patients with chemorefractory ovarian cancer who have a 'poor prognosis' and would otherwise not have been candidates for any proven or effective therapy.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Ovarian Neoplasms / mortality. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Australian and New Zealand Journal of Obstetrics and Gynaecology © 2010 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
  • (PMID = 21039384.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


22. Trimble EL, Christian MC: National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer; 2008 Mar-Apr;18 Suppl 1:26-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer.
  • On the basis of three large randomized phase III trials, the National Cancer Institute (NCI) issued a Clinical Announcement in January 2006 recommending that women with optimally debulked stage III ovarian cancer and their physicians consider a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy.
  • The NCI Clinical Announcement was issued as part of a broader educational campaign, designed in conjunction with professional societies, cancer centers, Clinical Trials Cooperative Groups, and cancer advocacy organizations.
  • The further development of IP chemotherapy in ovarian cancer requires additional clinical and translational research.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Infusions, Intravenous. Infusions, Parenteral. National Cancer Institute (U.S.). Practice Guidelines as Topic. United States

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336395.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Khouja MH, Baekelandt M, Nesland JM, Holm R: The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol; 2007 Oct;26(4):418-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
  • The present study addressed the impact of p14, p16, p57, and Ki-67 in a large cohort of uniformly treated patients with stage III ovarian cancer in relation to other clinicopathologic variables and prognosis.
  • We immunohistochemically studied 171 primary tumors from previously untreated patients with advanced ovarian carcinomas for expression of Ki-67, p16, p14, and p57.
  • Our results showed that Ki-67 represents an independent prognostic predictor in stage III ovarian cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p57 / biosynthesis. Ki-67 Antigen / biosynthesis. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p14ARF / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885492.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p14ARF
  •  go-up   go-down


24. Ball E, Morris-Stiff G, Coxon M, Lewis MH: Internal jugular vein thrombosis in a warfarinised patient: a case report. J Med Case Rep; 2007;1:184
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A stage III ovarian carcinoma was diagnosed and she underwent debulking of the tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1990 Mar-Apr;12(2):168-73 [2312283.001]
  • [Cites] Postgrad Med J. 1988 Jun;64(752):455-8 [3211826.001]
  • [Cites] Laryngoscope. 1985 Dec;95(12):1478-82 [4068866.001]
  • [Cites] J Laryngol Otol. 1998 Apr;112(4):383-6 [9659505.001]
  • [Cites] Curr Opin Hematol. 1998 Sep;5(5):339-42 [9776213.001]
  • (PMID = 18096068.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2234421
  •  go-up   go-down


25. Kojs Z, Glinski B, Pudelek J, Urbanski K, Karolewski K, Mitus J, Reinfuss M: [Follow-up of 70 patients with advanced ovarian cancer after negative second-look laparotomy]. J Gynecol Obstet Biol Reprod (Paris); 2006 Feb;35(1):16-22
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follow-up of 70 patients with advanced ovarian cancer after negative second-look laparotomy].
  • [Transliterated title] Abstention thérapeutique dans les cancers ovariens avancés après laparotomie de second look négative.
  • OBJECTIVES: To analyze the results of treatment of 70 patients with stage III and IV ovarian cancer after second look laparotomy with negative findings and to identify causes of failure and prognostic factors.
  • MATERIALS AND METHODS: Between 1985 and 1998, seventy patients with ovarian cancer stage III and IV were treated with surgery and at least six courses of chemotherapy with cisplatin doxarubicin and cyclophosphamide.
  • Adverse prognostic factors were: grade 3 differentiation, primary stage IIIC and IV, and residual infiltration exceeding 2 cm after first laparotomy.
  • The actuarial survival rate without evidence of disease at 5 years in patients with advanced ovarian cancer after second look negative laparotomy is 50%.
  • [MeSH-major] Laparotomy. Neoplasm Recurrence, Local. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Second-Look Surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446607.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Samsonia MD, Lesnovskaia EE, Kandelaki MA: [Clomiphene, ovarian hyperstimulation syndrome and pregnancy]. Georgian Med News; 2009 Jan;(166):26-9
Hazardous Substances Data Bank. CLOMIPHENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clomiphene, ovarian hyperstimulation syndrome and pregnancy].
  • In case of an ovarian hyperstimulation syndrome surgical treatment causes the regress of symptoms much faster than pharmacotherapy--during the resection of an ovary the concentration of estrogenes in blood is effectively reduced.
  • Frequent use of ovulation inductors (Clomiphene Gonadotrop(h)in) is accompanied by ovarian hyperstimulation syndrome.
  • This makes it difficult to verify the diagnosis of ovary cancer, particularly among pregnants.
  • Woman became pregnant after three courses of infertility treatment, but pregnancy was complicated with cardiac and lung insufficiency; the suspicion of stage III ovarian cancer aroused.
  • [MeSH-major] Clomiphene / therapeutic use. Estrogen Antagonists / therapeutic use. Infertility, Female / drug therapy. Ovarian Hyperstimulation Syndrome / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Ovarian hyperstimulation syndrome.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202213.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Estrogens; 1HRS458QU2 / Clomiphene
  •  go-up   go-down


27. Ferron G, Gesson-Paute A, Classe JM, Querleu D: Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study. Gynecol Oncol; 2005 Nov;99(2):358-61
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hyperthermic intraperitoneal chemotherapy (HIPEC) is being evaluated for patients with minimal residual or no residual disease after primary surgery and chemotherapy for stage III ovarian carcinoma.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced / methods. Laparoscopy / methods. Peritoneum / surgery
  • [MeSH-minor] Animals. Combined Modality Therapy. Feasibility Studies. Female. Infusions, Parenteral. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Ovarian Neoplasms / therapy. Pilot Projects. Sodium Chloride / administration & dosage. Swine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112182.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


28. Ceelen WP, Flessner MF: Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol; 2010 02;7(2):108-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three large randomized trials in patients with stage III ovarian cancer who underwent optimal cytoreduction have demonstrated a significant survival benefit when intraperitoneal chemotherapy was added to systemic therapy.
  • An increasing number of centers are initiating this multimodality therapy in ovarian cancer and colorectal cancer.
  • The optimal drug, dose and schedule for intraperitoneal delivery, the exact role of added HIPEC compared with cytoreduction alone, and the potential role of HIPEC in ovarian cancer and peritoneal mesothelioma are still undefined.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / therapy. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7646-53 [17699769.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):941-7 [17245567.001]
  • [Cites] Perit Dial Int. 2003 Nov-Dec;23(6):542-9 [14703194.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2754-60 [1451051.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:33-5 [18336397.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):148-54 [9624250.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):106-12 [16794395.001]
  • [Cites] Oncologist. 2008 Apr;13(4):410-4 [18448555.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):308-17 [11886010.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Aug;290(2):871-80 [10411604.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):100-4 [8349150.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):806-13 [15510161.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):681-5 [19103728.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):535-41 [17960463.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3117-25 [15837768.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):449-56 [10749603.001]
  • [Cites] Acta Oncol. 1997;36(4):375-81 [9247097.001]
  • [Cites] Cancer Treat Rep. 1978 Jan;62(1):1-11 [626987.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Mol Pharmacol. 2004 Oct;66(4):817-23 [15229296.001]
  • [Cites] Radiat Res. 1995 May;142(2):232-41 [7724740.001]
  • [Cites] Eur J Cancer. 1991;27(4):472-7 [1827723.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):57-9 [1998866.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Cancer Res. 1981 Jan;41(1):55-9 [7448776.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2426-32 [18521686.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):459-68 [15992694.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):583-92 [16862189.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):61-7 [14755505.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Mar;296(3):1035-42 [11181938.001]
  • [Cites] Chemotherapy. 2007;53(6):410-7 [17952000.001]
  • [Cites] J Surg Oncol. 2001 Feb;76(2):106-14 [11223836.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):325-32 [15297169.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2867-72 [17617517.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63 [17105988.001]
  • [Cites] Adv Anat Pathol. 2005 Nov;12(6):291-311 [16330927.001]
  • [Cites] J Am Med Assoc. 1955 Dec 31;159(18):1704-7 [13271133.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):68-73 [3335000.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):1-6 [4048968.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):138-45 [17182192.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Cancer Res. 1980 Feb;40(2):256-60 [6766084.001]
  • [Cites] World J Surg. 2007 Sep;31(9):1813-20 [17629740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):669-73 [1429089.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):176-80 [16996584.001]
  • [Cites] Perit Dial Int. 2008 Jan-Feb;28(1):6-12 [18178940.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1252-8 [1737387.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8782-8 [16361566.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):72-9 [19111247.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2702-13 [17653801.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):186-90 [16303281.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):405 [16894365.001]
  • [Cites] Am J Physiol. 1984 Apr;246(4 Pt 2):R597-607 [6720931.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):104-9 [17197972.001]
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):4-5 [19176238.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):450-4 [19135709.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):108-12 [12759776.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1232-7 [17317834.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(2):147-54 [9443628.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1166-70 [8630273.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):943-53 [18248392.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1801-5 [1919630.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Radiother Oncol. 2008 Aug;88(2):269-76 [18538874.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(17):2546-54 [18789678.001]
  • [Cites] Br J Surg. 2008 Sep;95(9):1164-71 [18690633.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):267-72 [11886004.001]
  • [Cites] Ann Oncol. 2007 Dec;18(12):1943-50 [17496308.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):38-42 [3931226.001]
  • [Cites] Cancer Chemother Pharmacol. 1985;14(2):104-7 [3971474.001]
  • [Cites] Br J Surg. 2002 Dec;89(12):1545-50 [12445064.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):4011-9 [16921055.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:20-5 [18336394.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;13(2):131-5 [6467498.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6744-9 [15475465.001]
  • (PMID = 20010898.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Fox SW, Lyon D: Symptom clusters and quality of life in survivors of ovarian cancer. Cancer Nurs; 2007 Sep-Oct;30(5):354-61
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom clusters and quality of life in survivors of ovarian cancer.
  • Ovarian cancer has nonspecific symptoms, and no screening tool is available for early diagnosis; therefore, only 19% of ovarian cancers are found at an early stage.
  • Given the late diagnosis, women with ovarian cancer often have a prolonged course of treatment and significant morbidity that lasts into survivorship.
  • The purpose of this study was to describe a symptom cluster and its relationship to quality of life in women with ovarian cancer who were recruited from an online cancer support group.
  • Most participants had stage III ovarian cancer, and nearly all (97%) had undergone treatment before the study.
  • A symptom cluster composed of depression and fatigue was identified using work by Kim and colleagues [Symptom clusters: concept analysis and clinical implications for cancer nursing.
  • Cancer Nurs. 2005;28(4):270-282].
  • These results suggest that fatigue and depression are significant problems for survivors of ovarian cancer.
  • [MeSH-major] Depressive Disorder / etiology. Fatigue / etiology. Ovarian Neoplasms / complications. Ovarian Neoplasms / rehabilitation. Pain / etiology. Quality of Life

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876181.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Lassmann S, Shen Y, Jütting U, Whiele P, Walch A, Gitsch G, Hasenburg A, Werner M: [Aurora-a is a predictive marker for stage III epithelial ovarian cancers]. Verh Dtsch Ges Pathol; 2007;91:225-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aurora-a is a predictive marker for stage III epithelial ovarian cancers].
  • [Transliterated title] Aurora-a ist ein prädiktiver Marker für Ovarialkarzinome des Stadiums III.
  • AIM: Overexpression of Aurora-A/STK15 kinase (hereafter AUKRA) is seen in a variety of epithelial cancers, such as gastrointestinal and gynaecological carcinomas.
  • Its role as prognostic and/or predictive marker for adjuvant therapy of patients with advanced ovarian cancer is however still unclear.
  • Therefore, the present study aimed at determining (1) the clinical value of AURKA expression (mRNA and protein) in 115 patients with ovarian carcinomas and (2) the basis of AURKA overexpression at the DNA level.
  • METHODS: Formalin-fixed and Paraffin-embedded tissue samples (ovarian carcinoma: n=115; non-neoplastic ovaries: n=28) were processed for microdissection and quantitative RT-PCR as well as for semi-quantitative immunohistochemistry (IHC) of tissue microarrays according to standardised protocols.
  • RESULTS: The results demonstrate significantly elevated AURKA expression at the mRNA and protein level in ovarian carcinomas as compared to non-neoplastic ovaries (p < 0.0001).
  • For patients with stage III ovarian carcinoma having been optimally debulked and receiving adjuvant Taxane-based chemotherapy, AURKA overexpression was significantly linked to prolonged overall survival (p = 0.02).
  • CONCLUSION: In summary, AURKA overexpression, which is regulated at the DNA level, is a novel predictive marker for a subgroup of patients with stage III ovarian carcinomas.
  • [MeSH-major] Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Aurora Kinase A. Aurora Kinases. Biomarkers, Tumor / analysis. DNA, Neoplasm / genetics. Dissection. Epithelial Cells / pathology. Female. Humans. In Situ Hybridization, Fluorescence. Neoplasm Staging. Ovary / cytology. Ovary / enzymology. Predictive Value of Tests. RNA, Messenger / genetics. Reference Values. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314619.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


31. Darcy KM, Tian C, Reed E: A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res; 2007 May 1;67(9):4474-81
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
  • To determine whether platinum-DNA adducts and/or mRNA expression of the excision nuclease excision repair cross-complementation group 1 (ERCC1) from peripheral blood leukocytes (PBL) were associated with clinical outcome in women with epithelial ovarian cancer (EOC), participants that had previously untreated, optimally resected, stage III EOC were randomized to paclitaxel plus cisplatin or carboplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA Adducts / blood. DNA-Binding Proteins / biosynthesis. Endonucleases / biosynthesis. Ovarian Neoplasms / blood. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483363.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; BG3F62OND5 / Carboplatin; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Markman M: Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer. Semin Oncol; 2006 Dec;33(6 Suppl 12):S3-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer.
  • After fading in popularity, three major phase III randomized trials (SWOG 8501/GOG 104, GOG 114, and GOG 172) have helped IP therapy to resurface as an acceptable alternative for selected stage III ovarian cancer patients with optimally debulked tumors.
  • This review article discusses the clinical data available from these three Gynecologic Oncology Group (GOG) studies (SWOG 8501/GOG 104, GOG 114, and GOG 172), supporting the use of a combination of IP and intravenous chemotherapy in patients with stage III ovarian cancer after surgical debulking.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Delivery Systems. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223444.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


33. Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D: Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol; 2008 Jan;15(1):339-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hyperthermic intraperitoneal chemotherapy (HIPEC) is being evaluated for patients with minimal residual or no residual disease after primary surgery and chemotherapy for stage III ovarian carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Dec;15(12):3623-4 [18726653.001]
  • (PMID = 17943387.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


34. Dällenbach P, Bonnefoi H, Pelte MF, Vlastos G: Yolk sac tumours of the ovary: an update. Eur J Surg Oncol; 2006 Dec;32(10):1063-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yolk sac tumours of the ovary: an update.
  • AIMS: Yolk sac tumours of the ovary (YST), also called endodermal sinus tumours (EST) are rare and highly malignant tumours of utmost importance occurring in children and young adults.
  • METHODS: We performed a literature search in the PubMed database and the reference lists of relevant articles concerning yolk sac tumours of the ovary.
  • FINDINGS AND CONCLUSION: There are no randomised studies relating to the management of YST of the ovary.
  • Prognosis nowadays is good in stage I and II but still comparable to that of ovarian epithelial cancer in stage III and IV.
  • The overall good prognosis is due to the fact that most of ovarian YST are diagnosed at an early stage where 5years survival reaches 95%.
  • [MeSH-major] Endodermal Sinus Tumor. Ovarian Neoplasms

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996238.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 74
  •  go-up   go-down


35. Stumpf M, Hasenburg A, Riener MO, Jütting U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, Werner M, Lassmann S: Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer; 2009 Nov 3;101(9):1513-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.
  • BACKGROUND: The aim of this study was to investigate the prognostic effect of tumour-infiltrating lymphocytes (TILs) in serous stage III ovarian carcinoma to determine TIL clonality and to correlate this to Her2/neu expression.
  • METHODS: Formalin-fixed and paraffin-embedded ovarian carcinomas were examined for CD20-, CD3-, CD4- and CD8-positive lymphocytes (n=100), and for Her2/neu-positive tumour cells (n=55/100) by immunohistochemistry.
  • RESULTS: CD20-positive B lymphocytes were present in 57.7% (stromal)/33.0% (intraepithelial) and CD3-positive T lymphocytes in 99.0% (stromal)/90.2% (intraepithelial) of ovarian carcinomas.
  • CONCLUSION: Improved survival of ovarian cancer patients is related to the infiltration, clonal selection and intraepithelial persistence of T lymphocytes.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Lymphocytes, Tumor-Infiltrating / immunology. Ovarian Neoplasms / immunology. Ovarian Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):73-9 [11216917.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2624-32 [12039923.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4090-5 [12651958.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):171-8 [7678601.001]
  • [Cites] J Immunol. 1993 Nov 15;151(10):5472-80 [8228239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6 [7831305.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):590-6 [15699022.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6598-607 [16166438.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii7-viii12 [16239238.001]
  • [Cites] Histol Histopathol. 2006 Jan;21(1):81-92 [16267789.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:195-8 [16343230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2640-1 [16371629.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12057-62 [16882720.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 [17360651.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2884-93 [17617519.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8378-87 [17804754.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7172-80 [18056198.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):415-20 [18037158.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):449-54 [18319334.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4410-7 [18802153.001]
  • [Cites] Breast J. 2008 Sep-Oct;14(5):487-91 [18821935.001]
  • [Cites] PLoS One. 2008;3(10):e3409 [18923710.001]
  • [Cites] Breast. 2008 Dec;17(6):604-10 [18656354.001]
  • [Cites] Cancer Immunol Immunother. 2009 Mar;58(3):449-59 [18791714.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):393-402 [19060844.001]
  • (PMID = 19861998.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2778517
  •  go-up   go-down


36. Rufián S, Muñoz-Casares FC, Briceño J, Díaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntané J, Pera C: Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol; 2006 Sep 15;94(4):316-24
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
  • BACKGROUND AND OBJECTIVES: Advanced ovarian cancer typically spreads in a diffuse intra-abdominal fashion.
  • The purpose of this study was to review patients submitted to surgical debulking and hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) and to evaluate the potential prognostic survival factors for advanced epithelial ovarian cancer in our center.
  • METHODS: A series of patients (N = 33) diagnosed of peritoneal carcinomatosis for epithelial ovarian cancer (stage III) from January 1997 to December 2004 submitted to radical surgery-peritonectomy and HIIC with paclitaxel was included in this study; 19 primary ovarian cancer and 14 recurrent ovarian cancer.
  • Patients with optimal cytoreduction R0 obtained survival rates of 63% at 5 years in recurrent ovarian cancer and 60% in primary ovarian cancer, 71% and 63%, respectively with associated subtotal infra-abdominal peritonectomy, and even better results if negative lymph nodes.
  • CONCLUSIONS: Radical surgery-peritonectomy with HIIQ has been shown to be a surgical procedure with high tolerability, low morbimortality, enhanced survival, and prolonged disease-free interval in patients with peritoneal carcinomatosis so much for recurrent or primary ovarian cancer.
  • [MeSH-major] Intraoperative Care. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Peritoneum / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Female. Humans. Infusions, Parenteral. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16917864.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A, IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada: Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol; 2007 Jun;105(3):747-56
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
  • OBJECTIVES: To evaluate the role of intraperitoneal (IP) chemotherapy as part of primary treatment in patients with advanced ovarian cancer and to develop standards of care within the context of current clinical practice.
  • CONCLUSION: The survival benefits with cisplatin-based IP chemotherapy may represent a significant improvement in the outlook for select patients with advanced ovarian cancer.
  • System-wide standards for the delivery of IP chemotherapy in Canada for patients with optimally debulked stage III ovarian cancer are offered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368522.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, Arjona A, Muñoz-Villanueva MC, Muntané J: The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol; 2009 Nov;11(11):753-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.
  • BACKGROUND AND OBJECTIVES: Peritoneal carcinomatosis in women frequently has an ovarian origin.
  • METHODS: A series of patients (N=26) diagnosed with peritoneal carcinomatosis for recurrent epithelial ovarian cancer (stage III) from January 1997 to December 2004 submitted to radical surgery/peritonectomy with optimal cytoreduction (R0-R1) were included in this study, 14 treated with HIPEC and 12 without HIPEC.
  • RESULTS: The variables age, histologic type, peritonectomy procedures, peritoneal cancer index (PCI) and lymph node affectation were similar in both groups.
  • CONCLUSIONS: HIPEC is a complement to radical surgery/ peritonectomy, which has been shown to be a surgical procedure with high tolerability, low morbimortality, enhanced survival and prolonged disease-free interval in patients with peritoneal carcinomatosis for recurrent ovarian cancer.
  • [MeSH-major] Hyperthermia, Induced / methods. Infusions, Parenteral / methods. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917539.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


39. Singhal P, Lele S: Intraperitoneal chemotherapy for ovarian cancer: where are we now? J Natl Compr Canc Netw; 2006 Oct;4(9):941-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal chemotherapy for ovarian cancer: where are we now?
  • Patients with advanced epithelial ovarian cancer are conventionally treated with intravenous (IV) platinum- and taxane-based chemotherapy to try to eradicate residual disease after optimal cytoreductive surgery, resulting in a median overall survival of 49 months.
  • The Gynecologic Oncology Group (GOG) conducted 3 large randomized, phase III clinical trials of intraperitoneal (IP) chemotherapy (GOG 104, 114, and 172) that clearly showed superior progression-free and overall survival with IP chemotherapy compared with IV chemotherapy.
  • Based on these clinical trials, the National Cancer Institute issued a clinical announcement recommending that women with stage III ovarian cancer who undergo optimal surgical cytoreduction be considered for IP chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020670.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


40. Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL, Barakat RR: A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol; 2009 Jan;112(1):6-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
  • OBJECTIVE: We previously reported that preoperative CA-125 may predict primary cytoreductive outcome in patients with stage III ovarian carcinoma (OC).
  • METHODS: We reviewed the records of all patients with advanced ovarian, tubal or peritoneal carcinoma who underwent primary cytoreduction at our institution between 1/01 and 4/05.
  • Primary disease sites were: ovary, 232 (84%); tubal, 9 (3%); and peritoneum, 36 (13%).
  • CONCLUSION: Following our change in surgical paradigm that the incorporated extensive upper abdominal procedures to attain optimal debulking, preoperative CA-125 did not predict the primary cytoreductive outcome of patients with advanced ovarian, tubal, or peritoneal carcinoma.
  • [MeSH-major] CA-125 Antigen / blood. Fallopian Tube Neoplasms / blood. Fallopian Tube Neoplasms / surgery. Ovarian Neoplasms / blood. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100916.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


41. Robinson WR, Davis N, Rogers AS: Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):891-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer.
  • The aim of this study was to determine the feasibility of two treatment regimens for ovarian cancers:.
  • A total of 102 subjects were identified who underwent surgery for stage III ovarian cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Middle Aged. Ovarian Neoplasms

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944912.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


42. Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M, Stein U, Royer B, Chauffert B, Pivot X: Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol; 2009;7:14
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
  • BACKGROUND: Intra-peritoneal (i.p.) chemotherapy is an encouraging treatment option for ovarian cancer with peritoneum involvement in addition with intravenous (i.v.) chemotherapy.
  • This study had assessed the feasibility of intra-operative i.p. chemotherapy in patients with peritoneal carcinoma of ovarian cancer.
  • METHODS: From January 2003 to February 2006, 47 patients with stage III ovarian cancer were treated with standard paclitaxel carboplatin intravenous chemotherapy and debulking surgery with intra-operative i.p. chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intraoperative Care. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Feasibility Studies. Female. Humans. Injections, Intraperitoneal. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rep. 1983 Mar;67(3):235-8 [6682012.001]
  • [Cites] Cancer Treat Rep. 1983 Dec;67(12):1085-92 [6228294.001]
  • [Cites] Gynecol Oncol. 1985 Jan;20(1):1-9 [4038390.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):43-6 [4048975.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(3):235-8 [3542268.001]
  • [Cites] Obstet Gynecol Surv. 1987 Sep;42(9):533-9 [3309746.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):227-31 [8428695.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Int J Cancer. 1999 May 31;81(5):779-84 [10328233.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2544-6 [15590959.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):1009-16 [16162978.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):27-32 [16368440.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):988-94 [16461779.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):415-21 [17503047.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] Cancer J. 2002 May-Jun;8 Suppl 1:S22-30 [12075699.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3 Pt 2):S8-15 [13129490.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):781-94 [14567031.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203 [14656280.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):147-51 [14751150.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):35-41 [14764027.001]
  • [Cites] Cancer Nurs. 2003 Dec;26(6 Suppl):16S-20S [15025408.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):387-92 [15070598.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):477-87 [15161446.001]
  • [Cites] Cancer Treat Rep. 1978 Jan;62(1):1-11 [626987.001]
  • (PMID = 19203351.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2644300
  •  go-up   go-down


43. Kanwar VS, Heath J, Krasner CN, Pearce JM: Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy. Pediatr Blood Cancer; 2008 May;50(5):1060-2
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
  • Advanced small cell carcinoma of the ovary (FIGO stage III or IV) is a rare and usually lethal tumor seen in adolescents and young women.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / therapy. Ovarian Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17914739.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrazoles; 0 / Pyrimidines; 0 / Sulfonamides; 11056-06-7 / Bleomycin; 4Z8R6ORS6L / Thalidomide; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


44. Rochet N, Jensen AD, Sterzing F, Munter MW, Eichbaum MH, Schneeweiss A, Sohn C, Debus J, Harms W: Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer; 2007 Dec 19;7:227
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.
  • BACKGROUND: The prognosis for patients with advanced epithelial ovarian cancer remains poor despite aggressive surgical resection and platinum-based chemotherapy.
  • Despite the clinically proven efficacy of whole abdominal irradiation, the use of radiotherapy in ovarian cancer has profoundly decreased mainly due to high treatment-related toxicity.
  • Patients with advanced ovarian cancer stage FIGO III (R1 or R2< 1 cm) after surgical resection and platinum-based chemotherapy will be treated with whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions.
  • The aim is to explore the potential of IMRT as a new method for WAI to decrease the dose to kidneys, liver, bone marrow while covering the peritoneal cavity with a homogenous dose, and to implement whole abdominal intensity-modulated radiotherapy into the adjuvant multimodal treatment concept of advanced ovarian cancer FIGO stage III.
  • [MeSH-major] Clinical Trials, Phase I as Topic / methods. Clinical Trials, Phase II as Topic / methods. Ovarian Neoplasms / radiotherapy. Radiotherapy, Adjuvant / methods. Radiotherapy, High-Energy / methods. Radiotherapy, Intensity-Modulated

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Dec;53(3):213-8 [10660201.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:3-11 [15839952.001]
  • [Cites] Forum (Genova). 2000 Oct-Dec;10(4):335-52 [11535984.001]
  • [Cites] Front Radiat Ther Oncol. 2002;36:25-34 [11842752.001]
  • [Cites] Radiother Oncol. 2002 Feb;62(2):163-71 [11937243.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1330-7 [11955746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):278-89 [12183002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21 [12527043.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):313-21 [12742271.001]
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):278-86 [12801256.001]
  • [Cites] Radiologe. 2003 Jun;43(6):448-54 [12827259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):516-21 [12957265.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):535-41 [14509952.001]
  • [Cites] Br J Radiol. 2003 Oct;76(910):673 [14512325.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):e136-43 [14528088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1019-32 [14575833.001]
  • [Cites] Acta Oncol. 2003;42(5-6):562-6 [14596514.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50 [14656286.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66 [14763172.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2755-6 [15187058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 May;8(5):893-7 [7107423.001]
  • [Cites] Cancer. 1985 May 1;55(9 Suppl):2285-90 [3919934.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):607-13 [2777649.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1203-6 [2254113.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1990 Jan;2(1):4-9 [2261388.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):30-5 [2026356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):835-45 [1555974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):847-51 [1555975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):853-8 [1555976.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1710-8 [8431909.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):26-32 [8438083.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii36-viii38 [16239235.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii7-viii12 [16239238.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3 [16611959.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):276-82 [16546279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Oct;4(9):912-39 [17020669.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):783-92 [17070570.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):97-103 [8244182.001]
  • [Cites] Semin Oncol. 1995 Jun;22(3 Suppl 6):78-83 [7541158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):543-9 [9635700.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):215-9 [10021304.001]
  • [Cites] Cancer Invest. 2004;22 Suppl 2:11-20 [15573741.001]
  • [Cites] Cancer Invest. 2004;22(5):815-7 [15581063.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):389-94 [15661226.001]
  • [Cites] Br J Radiol. 2000 May;73(869):459-69 [10884741.001]
  • (PMID = 18093313.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2212657
  •  go-up   go-down


45. Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Kulasingam S, Gynecologic Oncology Group: Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol; 2008 Sep 1;26(25):4144-50
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
  • PURPOSE: To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):476-81 [17688927.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1809-17 [11251013.001]
  • [Cites] J Palliat Med. 2002 Apr;5(2):263-70 [12006228.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(4):CD003911 [12519619.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1561-8 [1403035.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):656-63 [8033045.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2654-66 [7989941.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Natl Vital Stat Rep. 2006 Apr 19;54(14):1-40 [16681183.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):536-43 [16804928.001]
  • [Cites] Gynecol Oncol. 2006 Sep;102(3):432-9 [16860852.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):1-6 [16904166.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1513-22 [17354232.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • (PMID = 18757328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2654369
  •  go-up   go-down


46. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A: Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev; 2010;(10):CD006014
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interval debulking surgery for advanced epithelial ovarian cancer.
  • BACKGROUND: Interval debulking surgery (IDS), following induction or neoadjuvant chemotherapy, may have a possible role in treating advanced epithelial ovarian cancer (stage III to IV) where primary debulking surgery is not an option.
  • OBJECTIVES: To assess the effectiveness and complications of IDS for patients with advanced stage epithelial ovarian cancer.
  • SEARCH STRATEGY: We searched the Cochrane Gynaecological Cancer Group's Specialised Register to July 2009, the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2009, MEDLINE from January 1966 to June week 4 2009, and EMBASE from January 1966 to week 27 2009.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing survival of women with advanced epithelial ovarian cancer, who had IDS performed between cycles of chemotherapy after primary surgery with survival of women who had conventional treatment (primary debulking surgery and adjuvant chemotherapy).
  • AUTHORS' CONCLUSIONS: No conclusive evidence was found to determine whether IDS between cycles of chemotherapy would improve or decrease the survival rates of women with advanced ovarian cancer, compared with conventional treatment of primary surgery followed by adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery


47. Bolis G, Danese S, Tateo S, Rabaiotti E, D'Agostino G, Merisio C, Scarfone G, Polverino G, Parazzini F: Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:74-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study.
  • To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and chemotherapy with platinum-based schedules, we conducted a multicenter randomized clinical trial.
  • Patients with histologic diagnosis of epithelial ovarian cancer FIGO stage III or IV at first diagnosis; complete pathologic response at second-look laparotomy/laparoscopy or complete clinic response; and those who have had first-line therapy including surgery and one regimen containing cisplatin or carboplatinum were eligible for the study and were randomly allocated to epidoxorubicin 120 mg/sqm or no treatment.
  • The 3-year percent overall survival was 79.0% and 78.7%, respectively, in the no-treatment and epidoxorubicin groups (log-rank test, P= 0.93).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Epirubicin / therapeutic use. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515571.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ: Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol; 2005 Oct;99(1):71-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.
  • OBJECTIVE: A non-randomized comparison of outcome in women undergoing second-look laparotomy (SLL) or clinical follow-up, after receiving six cycles of combination chemotherapy with paclitaxel plus either cisplatin or carboplatin, for optimally resected stage III ovarian cancer.
  • Cancer was found in 46% of 294 (75%) patients undergoing SLL.
  • [MeSH-major] Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039699.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Ljuca D, Fatusić Z, Iljazović E, Ahmetović B: Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn J Basic Med Sci; 2007 May;7(2):111-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
  • In about 70% of cases, ovarian carcinoma has been diagnosed at an advanced stage.
  • Their serum concentrations in ovarian cancer patients may help in good monitoring of remission or progression during chemotherapy treatment.
  • In late 1950s and ear1y 1960s, when it was found out that malignant ovarian tumors were chemosensitive, their chemotherapy treatment has begun.
  • Now days, in the therapy of advanced stages of ovarian carcinoma combination of cisplatine or carboplatine with paclitaxel is considering as standard treatment.
  • Aim of this study was to determine serum uPA, suPAR and CEA in FIGO II and III patients with different histological type (serous, mucinous, clear cell tumor) before and after PT chemotherapy protocol during following three cycles.
  • In this prospective study we have analyzed 17 patients with ovarian carcinoma, those have been after surgery treated by chemotherapy.
  • Results of this study have shown that uPA, suPAR and CEA met criteria for prognostic markers for monitoring of successfulness of platina/taxol chemotherapy protocol for serous, mucinous and clear cell tumor FIGO II and III stage of ovarian carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489744.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; BG3F62OND5 / Carboplatin; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


50. Yen MS, Twu NF, Lai CR, Horng HC, Chao KC, Juang CM: Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol; 2009 Sep;114(3):415-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
  • OBJECTIVE: Intraperitoneal (IP) chemotherapy has gained enthusiasm in the treatment of ovarian cancer.
  • METHODS: Between January 2001 and December 2007, 367 patients with stage III epithelial ovarian cancer underwent randomized trial for IP/IV chemotherapy were recruited to construct a nomogram, which is a graphical representation of Cox proportional hazards model adopting six weighted risk factors including age, CA125, IP/IV delivery, stage, histology, and upper abdominal metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2010 May;117(2):390; author reply 391 [20149423.001]
  • (PMID = 19577277.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


51. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, Gynecologic Oncology Group: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2007 Feb 1;25(4):437-43
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: A Gynecologic Oncology Group (GOG) randomized phase III trial (GOG 172) in optimal stage III epithelial ovarian cancer showed that intravenous (IV) paclitaxel plus intraperitoneal (IP) cisplatin and paclitaxel significantly lengthened progression-free survival and overall survival compared with IV paclitaxel and cisplatin.
  • The Functional Assessment of Cancer Therapy-Trial Outcome Index (FACT-TOI; which includes physical, functional, and ovarian subscales) and neurotoxicity (Ntx) and abdominal discomfort (AD) subscales were used to assess patient-reported outcomes.
  • RESULTS: Physical and functional well-being and ovarian cancer symptoms were significantly worse in the IP arm before cycle 4 (P < .001) and 3 to 6 weeks after treatment (P = .001 for FACT-TOI).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


52. Vergote I, van Gorp T, Amant F, Leunen K, Neven P, Berteloot P: Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer; 2008 Mar-Apr;18 Suppl 1:11-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of debulking surgery in advanced ovarian cancer.
  • It is clear that primary debulking remains the standard of care within the treatment of advanced ovarian cancer (FIGO stage III and IV).
  • In this situation, based on the randomized European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group trial, interval debulking by an experienced surgeon improves survival in some patients who did not undergo optimal primary debulking surgery.
  • However, we will have to wait for the results of future randomized trials to know whether neoadjuvant chemotherapy followed by interval debulking surgery is a good alternative to primary debulking surgery in stage IIIc and IV patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336393.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 66
  •  go-up   go-down


53. Tummala MK, Alagarsamy S, McGuire WP: Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer? Expert Rev Anticancer Ther; 2008 Jul;8(7):1135-47
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
  • Epithelial ovarian cancer is the leading cause of death from gynecological cancer in most of the Western world, and long-term survival remains poor despite good initial response to systemic therapy after debulking surgery.
  • In spite of three National Cancer Institute-sponsored randomized trials demonstrating clinical benefit with intraperitoneal therapy in patients with advanced ovarian cancer, the fact remains that it is not uniformly accepted by the gynecologic oncology community in the USA and is rarely used by clinicians in Europe.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588458.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


54. American College of Obstetricians and Gynecologists: ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer. Obstet Gynecol; 2008 Jan;111(1):249
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
  • Postoperative intravenous (IV) chemotherapy for advanced stage ovarian cancer has been the standard treatment .
  • Combination IV/IP chemotherapy may be an option for well counseled, carefully selected patients with optimally debulked stage III ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Infusions, Parenteral. Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165421.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


55. Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, Markman M: Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol; 2009 Aug;114(2):206-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
  • OBJECTIVE: While primary cisplatin-based intraperitoneal chemotherapy has been shown to favorably impact survival in small-volume residual advanced ovarian cancer, there is a need to develop strategies that improve the effectiveness of this approach.
  • The provocative PFS in a subset of individuals should encourage the development of alternative strategies designed to optimize the delivery of regional therapy in ovarian cancer management.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3312-22 [11454878.001]
  • [Cites] Gynecol Oncol. 2003 Feb;88(2):130-5 [12586591.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):405-10 [9469322.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):46-51 [10458217.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1419-25 [19224846.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2 Suppl 1):S18-9 [17027073.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3093-100 [10963637.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):114-9 [16959305.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):692-702 [17238181.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):667-71 [17368526.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2811-8 [17602086.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • (PMID = 19464730.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA032102-28S2; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA032102-28S2; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / CA67575
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS113603; NLM/ PMC2703693
  •  go-up   go-down


56. Petignat P, Vlastos AT, Bonnefoi H, Boulvain M: [What's new in gynecology in 2006?]. Rev Med Suisse; 2007 Jan 10;3(93):18-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ovarian cancer is usually limited to the peritoneal cavity and IP chemotherapy is associated with increased local concentrations.
  • A benefit of this approach on survival was shown in three randomized trials and justifies the recommendation of this treatment for women with a Stage III ovarian cancer, after optimal surgery.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354655.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 19
  •  go-up   go-down


57. Rosa DD, Clamp A, Mullamitha S, Ton NC, Lau S, Byrd L, Clayton R, Slade RJ, Kitchener HC, Shanks JH, Wilson G, McVey R, Hasan J, Swindell R, Jayson GC: The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol; 2006 Jun;32(5):588-91
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
  • BACKGROUND: To study the effect of the interval between surgery and the start of chemotherapy in the treatment of patients with advanced ovarian cancer.
  • RESULTS: Three hundred and ninty-four stage III ovarian cancer patients were analysed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569491.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601746
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen; 0 / Platinum Compounds; BG3F62OND5 / Carboplatin
  •  go-up   go-down


58. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M, Lage H: ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res; 2006 Dec 1;12(23):7149-58
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
  • PURPOSE: Cisplatin resistance is a major obstacle in the treatment of ovarian carcinoma.
  • Here, we show that ABCC2 can be localized in the cytoplasmic membrane as well as in the nuclear membrane of various human tissues including ovarian carcinoma cells.
  • EXPERIMENTAL DESIGN: For the subcellular detection of ABCC2, immunohistochemistry was done using 41 Federation Internationale des Gynaecologistes et Obstetristes stage III ovarian carcinoma specimens prepared before treatment with cisplatin-based schemes and 35 specimens from the same group after chemotherapy.
  • Furthermore, 11 ovarian carcinoma cell lines as well as tissue microarrays consisting of various human tissues were analyzed.
  • In ovarian carcinoma cells, it correlated with resistance against cisplatin, whereas localization in the cytoplasmic membrane did not.
  • CONCLUSIONS: ABCC2 confers resistance to cisplatin of ovarian carcinoma in cell culture systems and in clinics when expressed in the nuclear membrane.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. Membrane Transport Proteins / metabolism. Multidrug Resistance-Associated Proteins / metabolism. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145840.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / multidrug resistance-associated protein 2; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Marchini S, Marabese M, Marrazzo E, Mariani P, Cattaneo D, Fossati R, Compagnoni A, Fruscio R, Lissoni AA, Broggini M: DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol; 2008 Mar;19(3):501-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DeltaNp63 expression is associated with poor survival in ovarian cancer.
  • BACKGROUND: P63 belongs to the 'p53 family' whose role in cancer progression has been recently revisited in light of the plethora of splicing variants that are generated.
  • We analyzed the expression of the full-length TAp63 gene and its dominant-negative form deltaNp63 in ovarian cancer biopsies to correlate their expression with clinical outcome.
  • MATERIALS AND METHODS: Real-time RT-PCR analysis was used to determine the levels of TAp63 and deltaNp63 in 83 stage I and in 86 stage III ovarian cancer biopsies and in seven human ovarian cancer cell.
  • RESULTS: TAp63 levels were comparable in stage I and stage III, but deltaNp63 levels increased 77-fold in stage III, independently of the p53 status.
  • CONCLUSIONS: Data indicate a role for deltaNp63 as a potential biomarker to predict patient's outcome and tumor progression in ovarian cancer.
  • This would have particularly clinical relevance in ovarian cancer where the high rate of mortality reflects our lack of knowledge of molecular mechanisms underlying cell progression toward malignancy.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998283.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


60. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, Veenstra TD, Conrads TP, Goldsmith P, Fishman D, Petricoin EF 3rd, Liotta LA: Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem; 2005 Oct;51(10):1933-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of albumin-associated peptides and proteins from ovarian cancer patients.
  • We used this method to analyze pooled sera from a human disease study set (high-risk persons without cancer, n = 40; stage I ovarian cancer, n = 30; stage III ovarian cancer, n = 40) to demonstrate the feasibility of this approach as a discovery method.
  • Several proteolytic fragments of larger molecules that may be cancer-related were confirmed immunologically in blood by Western blotting and peptide immunocompetition.
  • BRCA2, a 390-kDa low-abundance nuclear protein linked to cancer susceptibility, was represented in sera as a series of specific fragments bound to albumin.
  • [MeSH-major] Albumins / chemistry. Ovarian Neoplasms / diagnosis. Peptides / chemistry. Proteins / chemistry


61. Chen F, Shen K, Lang JH, Huang HF, Wu M: [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary]. Zhonghua Yi Xue Za Zhi; 2005 May 18;85(18):1257-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary].
  • OBJECTIVE: To investigate the clinical features, treatment and prognosis of patients with double primary carcinoma of uterine corpus and ovary.
  • METHODS: The clinical features, operation findings, treatment and prognosis of 36 patients with double primary carcinoma of uterine corpus diagnosed and treated in the last 20 years, 25 with typical endometrial adenocarcinoma and endometrioid carcinoma of the ovary (group A) 11 with non-endometrioid carcinoma in uterine corpus and/or ovary (group B) were respectively analyzed.
  • The 1, 3, and 5-year survival rates of these 36 patients were 89%, 83%, and 75% respectively, all equal to those of the patients with stage I ovarian cancer.
  • CONCLUSION: The prognosis of double primary carcinoma of uterine corpus and ovary is rather good.
  • It is necessary to distinguish double primary carcinoma of uterine corpus and ovary from stage II ovarian cancer and stage III endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029611.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Noor S, Khan R, Hollingworth A: An unusual presentation of Stage III ovarian carcinoma. J Obstet Gynaecol; 2005 Aug;25(6):619-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of Stage III ovarian carcinoma.
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234164.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


63. Van Gorp T, Amant F, Neven P, Berteloot P, Leunen K, Vergote I: The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer. Cancer Treat Res; 2007;134:387-402
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer.
  • [MeSH-major] Minimally Invasive Surgical Procedures. Neoadjuvant Therapy. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633068.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


64. Escobar PF, Michener CM, Rose PG: Second-look operation improves survival in suboptimal, debulked, stage III ovarian cancer. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1258; author reply 1259
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-look operation improves survival in suboptimal, debulked, stage III ovarian cancer.
  • [MeSH-major] Gynecologic Surgical Procedures. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):19-25 [15670292.001]
  • (PMID = 16343227.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement